---
title: "Lysergide (DT120) in Generalized anxiety disorder: Long-term morbidity"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Long-term morbidity. Topics: Psychiatric comorbidity: World Mental Health Surveys; Major depressive episode: onset after generalized anxiety disorder in the National Comorbidity Survey follow-up; Substance use, mood, anxiety, and personality disorders: National Epidemiologic Survey on Alcohol and Related Conditions; Comorbidity and the course of anxiety disorders; 5 further topics. 9 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Psychiatric comorbidity: World Mental Health Surveys

> “Lifetime comorbidity is high (81.9% [0.7%]), particularly with mood (63.0% [0.9%]) and other anxiety (51.7% [0.9%]) disorders.”
> “The single most common comorbid condition was major depressive disorder, which was found in 52.6%(0.9%) of lifetime cases and 40.9%(1.3%) of 12-month cases of GAD worldwide.”

Source: [Ruscio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5594751/)

<a id="topic-2.2.1.7-2"></a>

### Major depressive episode: onset after generalized anxiety disorder in the National Comorbidity Survey follow-up

> “Data were analyzed from the nationally representative two-wave panel sample of 5001 respondents who participated in the 1990-2 National Comorbidity Survey (NCS) and the 2001-03 NCS follow-up survey.”
> “Baseline MDE significantly predicted subsequent GAD onset but not persistence. Baseline GAD significantly predicted subsequent MDE onset and persistence.”
> “The associations of each disorder with the subsequent onset of the other attenuated with time since onset of the temporally primary disorder, but remained significant for over a decade after this onset.”
> “The OR of temporally primary MDE predicting subsequent first onset of GAD is 2.7 (Table 1, Part I). The OR of temporally primary GAD predicting subsequent first onset of MDE is 3.2 (Table 1, Part II).”

Source: [Kessler et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2745899/)

<a id="topic-2.2.1.7-3"></a>

### Substance use, mood, anxiety, and personality disorders: National Epidemiologic Survey on Alcohol and Related Conditions

> “GAD was highly co-morbid with substance use, and other anxiety, mood, and personality disorders. Co-morbidity in GAD was not substantially greater than for most other Axis I and II disorders.”
> “Individuals co-morbid for GAD and each mood disorder were more disabled than those with pure forms of GAD or each mood disorder.”

Source: [Grant et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16202187/)

<a id="topic-2.2.1.7-4"></a>

### Comorbidity and the course of anxiety disorders

> “Symptoms are generally not pathognomonic of individual anxiety disorders, and anxiety disorder comorbidity is substantial: 48–68% of adults with one anxiety disorder fulfil the criteria for another concurrent anxiety disorder.”
> “people with multiple disorders have higher severity, disability, and a poorer disease course compared with people who have a single anxiety disorder.”
> “Anxiety and depression comorbidity signifies higher disorder severity, burden, and chronicity compared with individual disorders.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

> “The overall clinical course was worsened by several comorbid psychiatric conditions, including major depression and alcohol and other substance use disorders, and by comorbidity of generalized anxiety disorder and panic disorder with agoraphobia.”
> “Among patients with generalized anxiety disorder, those with comorbid panic disorder with agoraphobia had a significantly lower likelihood of recovering from generalized anxiety disorder, compared to those without comorbid panic disorder with agoraphobia (risk ratio=0.67, p<0.05).”

Source: [Bruce et al. (2005)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3272761/)

<a id="topic-2.2.1.7-5"></a>

### Cardiovascular disease: incident disease in meta-analyses of population cohorts

> “The meta-analysis comprised 37 papers (n = 1 565 699). The follow-up ranged from 1 to 24 years. Anxiety was associated with a 52% increased incidence of CVD (hazard ratio = 1.52, 95% CI 1.36-1.71). The risk seemed independent of traditional risk factors and depression.”

Source: [Batelaan et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26932485/)

> “Twenty studies reporting on incident CHD comprised 249,846 persons with a mean follow-up period of 11.2 years. Anxious persons were at risk of CHD (hazard ratio [HR] random: 1.26; 95% confidence interval [CI]: 1.15 to 1.38; p < 0.0001) and cardiac death (HR: 1.48; 95% CI: 1.14 to 1.92; p = 0.003), independent of demographic variables, biological risk factors, and health behaviors.”

Source: [Roest et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20620715/)

<a id="topic-2.2.1.7-6"></a>

### Cardiovascular events in stable coronary heart disease: Heart and Soul Study

> “One thousand fifteen outpatients with stable CHD followed up for a mean (SD) of 5.6 (1.8) years.”
> “The age-adjusted annual rate of cardiovascular events was 9.6% in the 106 participants with GAD and 6.6% in the 909 participants without GAD (P = .03).”
> “After adjustment for demographic characteristics, comorbid conditions (including major depressive disorder), cardiac disease severity, and medication use, GAD remained associated with a 62% higher rate of cardiovascular events (hazard ratio, 1.62; 95% confidence interval, 1.11-2.37; P = .01).”

Source: [Martens et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20603456/)

<a id="topic-2.2.1.7-7"></a>

### Other somatic conditions

> “with emerging evidence of increased onset risk of other somatic conditions, including stroke, diabetes, arthritis, and lung disease than in the general population.”
> “Patients with diverse somatic illnesses, including cardiovascular, respiratory, or musculoskeletal disease, have an increased risk of comorbid anxiety.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.7-8"></a>

### Complications listed in a clinical review

> “Complications of generalized anxiety disorder can also lead to, or worsen, other mental and physical conditions, including:”
> “Depression (often presents concomitantly with an anxiety disorder)”
> “Drug or alcohol use disorder”
> “Gastrointestinal tract problems”
> “Social isolation”
> “Issues functioning at work or school”
> “Untreated anxiety disorders may contribute to severe depression and alcohol or other substance use disorders.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.7-9"></a>

### Multimorbidity and depressive symptoms by symptom severity: sponsor-funded National Health and Wellness Survey analyses

> “Of 43,472 adults included in analyses, 88.8%, 2.2%, 3.5%, 2.8%, and 2.7% were classified as control, GAD with no/minimal, mild, moderate, and severe subgroups, respectively.”
> “While almost 50% of the control group reported no comorbidities, 1.1% of the severe cohort had no comorbidities. 56% and 63% individuals with moderate and severe GAD reported having 4 or more comorbidities, compared to 10% in the control group.”
> “The mild cohort had an adjusted mean of 2.7 times more comorbidities compared to the control group, 3.0 times in moderate and 3.3 times in severe GAD.”
> “Name of Sponsoring Organization(s): MindMed”

Source: [Ferries et al. (2025)](https://www.hmpgloballearningnetwork.com/node/371502)

> “The study also revealed that 65% of those reporting GAD symptoms also reported major depressive disorder (MDD) symptoms.”

Source: [MindMed suicidal ideation study announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/194/new-mindmed-retrospective-study-presented-at-psych-congress-2025-reveals-high-rates-of-suicidal-ideation-si-in-adults-with-generalized-anxiety-disorder-gad)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
